First IL-17A biologic approved for polymyalgia rheumatica - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

First IL-17A biologic approved for polymyalgia rheumatica

  • By

  • Mouj Hijazi

  • November 17, 2026

  • 2 min

Share

Objective:

The article examines the objective, findings, and clinical context described in First IL-17A biologic approved for polymyalgia rheumatica.

Approach:
  • Approval: The FDA approved secukinumab (Cosentyx) 150 mg for this population, making it the first IL-17A inhibitor approved for PMR in the United States.
  • Trial: REPLENISH was a randomized, double-blind, placebo-controlled phase 3 trial of 381 adults with PMR and at least one relapse during glucocorticoid tapering. Participants received secukinumab 150 mg, secukinumab 300 mg, or placebo for 52 weeks, alongside a 24-wee…
  • Primary endpoint: Sustained remission at week 52 required remission by week 12, maintained without a PMR flare or new giant cell arteritis diagnosis requiring rescue treatment.
Key Findings:
  • Sustained remission occurred in 40.5% of patients receiving secukinumab 150 mg and 20.5% receiving placebo.
  • Mean adjusted cumulative glucocorticoid dose through week 52 was 1,683.2 mg with secukinumab 150 mg and 2,093 mg with placebo.
  • Median time to rescue treatment for a PMR flare was 282 days with secukinumab 150 mg and 157 days with placebo.
  • Serious adverse events occurred in 15.9% of the secukinumab 150 mg group and 14.2% of the placebo group. Hypersensitivity reactions occurred in 14% versus 9%, and urinary tract infections in 13% versus 7%.
  • A fatal case of cryptococcal meningitis occurred in a secukinumab-treated patient.
Interpretation:

The FDA-approved prescribing information recommends secukinumab 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, then every 4 weeks, in combination with a glucocorticoid taper. It may be continued alone after glucocorticoids are discontinued.

Limitations:
  • The supplied context reports results for the 150 mg dose versus placebo but does not provide results for the 300 mg dose.
  • The supplied context does not report additional trial details such as participant demographics or confidence intervals.
Conclusion:

The prescribing information warns of serious infections and inflammatory bowel disease, advises tuberculosis evaluation and age-appropriate vaccinations before treatment, and contraindicates use in patients with serious hypersensitivity to secukinumab or its excipients.

Sources:

Original Source(s)

Related Content